<DOC>
	<DOCNO>NCT00228397</DOCNO>
	<brief_summary>To evaluate safety tolerability long-term therapy 3 dose level oral CCI-779 administer subject relapse MS complete study 3066A2-205-WW .</brief_summary>
	<brief_title>Study Evaluating CCI-779 Relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Subjects relapsingremitting MS secondary progressive MS relapse . Successful completion study 3066A2205WW major protocol violation . Pregnancy lactation . Clinically important abnormality physical examination , vital sign , electrocardiogram ( ECG ) perform last visit study 3066A2205WW ( day 252 ) . Any adverse event finding observe study 3066A2205WW opinion investigator would preclude subject 's entry extension study . Please refer section 16.2 'Discontinuation Withdrawal Subjects ' regard withdrawal patient clinical abnormality hematology laboratory test result obtain last visit doubleblind active phase study 3066A2205WW .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Multiple Sclerosis</keyword>
</DOC>